BICX (BioCorRx) Moat Score: 2/10 (As of Jul. 08, 2026)


BICX BioCorRx Inc BICX
37 GF Score
Price $0.40
GF Value $2.76
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is BioCorRx Moat Score?

BioCorRx BICX 37 Moat Score is 2 as of Jul. 08, 2026. GuruFocus rates BICX with a GF Score™ of 37/100 and a GF Value™ of $2.76 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 676 Healthcare Providers & Services companies, BioCorRx ranks better than 79.29% on this metric.

BioCorRx has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

BioCorRx has No Moat: BioCorRx Inc has very weak competitive advantages. It lacks significant market share, brand strength, and customer loyalty. The company does not possess substantial intellectual property or regulatory barriers to entry.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioCorRx might have No Moat - Very weak/transient advantages.

BioCorRx  (OTCPK:BICX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioCorRx Moat Score Related Terms

BICX vs HLYK, AMS, BMGL: Moat Score Comparison

For the Medical Care Facilities subindustry, BioCorRx's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCorRx Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioCorRx's Moat Score distribution charts can be found below:

* The bar in red indicates where BioCorRx's Moat Score falls into.


BICX
37GF Score
BioCorRx Inc BICX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
BioCorRx (BICX) has a Moat Score of 2 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BioCorRx ranks #140 out of 676 companies in the Healthcare Providers & Services industry, placing it in the top 20.7%.
Is BioCorRx's Moat Score too high?
BioCorRx's current Moat Score is 2. Based on the distribution chart, BioCorRx ranks #140 out of 676 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, BioCorRx has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioCorRx's Moat Score compare to HLYK and AMS?
According to the Healthcare Providers & Services industry distribution chart, BioCorRx ranks #140 out of 676 companies for Moat Score. This places BioCorRx in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. BioCorRx's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCorRx stock overvalued right now?
Based on GuruFocus' analysis, BioCorRx (BICX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.76, compared to a current price of $0.40 — trading 85.5% below its estimated fair value. The current Moat Score is 2. BioCorRx's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BioCorRx (BICX), the current Moat Score is 2 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCorRx (BICX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCorRx stock appears to be undervalued. The current stock price of $0.40 is trading 85.5% below its estimated GF Value™ of $2.76. GuruFocus considers BioCorRx to be Possible Value Trap.

Key valuation signals for BICX:

  • Moat Score: 2
  • GF Value™: $2.76 vs. price of $0.40 (85.5% below fair value)
  • GF Score™: 37/100 with 7 warning signs

No single metric tells the full story. See the BICX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioCorRx Business Description

Address 2390 East Orangewood Avenue, Suite 570, Anaheim, CA, USA, 92806
BioCorRx Inc through its subsidiaries, develops and provides addiction treatment solutions, offering an approach to the treatment of substance use and other related disorders. The company makes the Beat Addiction Recovery Program and UnCraveRx Weight Loss Management Program available to healthcare providers to utilize when the healthcare provider determines it is medically appropriate and indicated for their patients. Its products include BICX102 and BICX104. It operates in a single segment.
37GF Score

Get the complete analysis for BICX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$2.76
GF Value